TY - JOUR
T1 - Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis
AU - Morishita, Koichi
AU - Ito, Nami
AU - Koda, Sayaka
AU - Maeda, Megumi
AU - Nakayama, Kotarosumitomo
AU - Yoshida, Kiyoshi
AU - Takamatsu, Shinji
AU - Yamada, Makoto
AU - Eguchi, Hidetoshi
AU - Kamada, Yoshihiro
AU - Miyoshi, Eiji
N1 - Funding Information:
We would like to thank Kayoko Kidowaki-Shimizu, Tatsuo Kurosawa, and Mutsuhiro Date of the Fuji Film Corporation for providing the Fuc-Hpt ELISA kit, using 10-7G mAb.
Funding Information:
This study was supported by a JSPS KAKENHI grant [grant number 16H05226] from the Japan Society for the Promotion of Science.
Publisher Copyright:
© 2018
PY - 2018/12
Y1 - 2018/12
N2 - Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.
AB - Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients. In this study, we measured Fuc-Hpt using a lectin-antibody enzyme-linked immunosorbent assay (ELISA) or a novel ELISA system that used a glycan antibody for Fuc-Hpt. Hpt is known to be divided into three phenotypes (Hpt1–1, Hpt2–1, and Hpt2–2), depending on its genetic background. Normal levels of serum Hpt are different in each Hpt phenotype and these phenotypes are associated with the incidence of several human diseases. Here, we investigated how Hpt phenotype affected measurements of Fuc-Hpt, using two kinds of ELISA. Interestingly, we found that serum Fuc-Hpt levels were dramatically lower in the Hpt1–1 phenotype for both types of ELISA. For Hpt2–1 and Hpt2–2, we observed significantly increased serum Fuc-Hpt levels in patients with pancreatic cancer. When cases of the Hpt1–1 phenotype were depleted, our receiver operating characteristic (ROC) curve analyses showed that the area under the curve (AUC) value for pancreatic cancer diagnosis increased in each ELISA. Taken together, our results indicate that Hpt phenotype is a critical for the clinical application of Fuc-Hpt as a cancer biomarker.
UR - http://www.scopus.com/inward/record.url?scp=85053807473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053807473&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2018.09.001
DO - 10.1016/j.cca.2018.09.001
M3 - Article
C2 - 30189188
AN - SCOPUS:85053807473
SN - 0009-8981
VL - 487
SP - 84
EP - 89
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -
